Pharmaceuticals Italy

Italy KRAS Inhibitors Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Italy KRAS Inhibitors Market Industry Trends and Forecast to 2034: Segmented by (Target, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Italy · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $22.3 Mn Placeholder estimate
Estimate 2025 $30.0 Mn 2.7% of the global market
Projected 2034 $444.2 Mn 1,379.5% Adds $414.2 Mn over 9 forecast years
CAGR 2025–2034 34.9% Faster than 98% of 180 Pharmaceuticals markets here
Key players 5
  • Italy is 2.75% of the global market.
  • In Europe, the largest is Germany at $36.5 Mn.
  • Fastest growing: Italy (this report) at 34.9% a year.
  • Italy ranks 4th of 6 by size in Europe.

Market size projection

Italy

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$414.2 Mn total, 2026–2034

Year-by-year market size, 2024–2034
KRAS Inhibitors Market market size by year, Italy
YearMarket sizeChange that yearSince 2025
2024 (estimate) $22.3 Mn — —
2025 (base) $30.0 Mn +$7.8 Mn —
2026 (forecast) $40.5 Mn +$10.5 Mn +34.9%
2027 (forecast) $54.6 Mn +$14.1 Mn +82%
2028 (forecast) $73.7 Mn +$19.1 Mn +145.5%
2029 (forecast) $99.4 Mn +$25.7 Mn +231.2%
2030 (forecast) $134.1 Mn +$34.7 Mn +346.7%
2031 (forecast) $181.0 Mn +$46.8 Mn +502.7%
2032 (forecast) $244.1 Mn +$63.2 Mn +713%
2033 (forecast) $329.3 Mn +$85.2 Mn +996.7%
2034 (forecast) $444.2 Mn +$114.9 Mn +1,379.5%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Italy KRAS Inhibitors Market Analysis at a glance
Market size, 2025$30.0 Mn placeholder estimate
Forecast, 2034$444.2 Mn placeholder estimate
Growth (CAGR), 2025–203434.9% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTarget, indication and end user (see all)
Key playersAmgen Inc., Bristol-Myers Squibb, Eli Lilly and Company, Revolution Medicines, Novartis AG (see all)
Regulator in ItalyAIFASource: Italian Medicines Agency (AIFA). Checked 14 Nov 2026.
Active clinical trials59 in ItalySource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Italy. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Italy KRAS Inhibitors Market Analysis Executive Summary

KRAS inhibitors target a common cancer-causing gene mutation that was long thought impossible to drug, mainly in lung and bowel cancers.

Key segments of the KRAS Inhibitors market include target (KRAS G12C, KRAS G12D and Pan-KRAS) and indication (Non-Small Cell Lung Cancer, Colorectal Cancer and Pancreatic Cancer).

Bar chart: Italy KRAS Inhibitors market size, 2024–2034, placeholder estimates. $22.3 Mn in 2024, $30.0 Mn in 2025 and $444.2 Mn in 2034, 34.9% CAGR.
Italy KRAS Inhibitors market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Italy KRAS Inhibitors Market Dynamics

Market Growth Drivers

Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the KRAS Inhibitors market. Faster approvals and new combinations are improving survival.

Opportunity

Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the KRAS Inhibitors market.

Market Restraints

High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the KRAS Inhibitors market, especially in low- and middle-income countries.

Competitive Landscape for KRAS Inhibitors Market in Italy

The KRAS Inhibitors market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for KRAS Inhibitors Market in Italy

KRAS Inhibitors in Italy: rules, payment and research

Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by AIFA, the Italian Medicines Agency, which also negotiates prices and reimbursement.⁠[1] The National Health Service (SSN), run by the regions, gives universal cover, and AIFA decides which medicines it pays for.⁠[2] ClinicalTrials.gov lists 59 studies on KRAS Inhibitors that are recruiting, active or about to start in Italy.⁠[3]

[1] Italian Medicines Agency (AIFA). Checked 14 Nov 2026.

[2] Italian Ministry of Health. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Italy. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for KRAS Inhibitors. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Italy.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in KRAS Inhibitors right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

KRAS Inhibitors in context

Italy compared

  • Health spending per person: 3,398 US$ per person (2024). World: 1,317 US$ per person (2023). 4th highest of the 6 countries we cover in Europe.[1]
  • Doctors: 4.19 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 4th highest of the 6 countries we cover in Europe.[2]
  • People aged 65 and over: 25.1% of people (2025). World: 10.4% of people (2025). Highest of the 6 countries we cover in Europe.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the KRAS Inhibitors market in Italy?
Placeholder estimate: about $30.0 Mn in 2025, rising to about $444.2 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the KRAS Inhibitors market in Italy growing?
Placeholder estimate: about 34.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the KRAS Inhibitors market report cover?
The report splits the market by target (KRAS G12C, KRAS G12D, Pan-KRAS), indication (Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the KRAS Inhibitors market?
Key players include Amgen Inc., Bristol-Myers Squibb, Eli Lilly and Company, Revolution Medicines and Novartis AG.
What is driving the KRAS Inhibitors market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the KRAS Inhibitors market. Faster approvals and new combinations are improving survival.
Who regulates KRAS Inhibitors in Italy?
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by AIFA, the Italian Medicines Agency, which also negotiates prices and reimbursement. Source: Italian Medicines Agency (AIFA). Checked 14 Nov 2026.
How is healthcare paid for in Italy?
The National Health Service (SSN), run by the regions, gives universal cover, and AIFA decides which medicines it pays for. Source: Italian Ministry of Health. Checked 14 Nov 2026.
How many clinical trials on KRAS Inhibitors are running in Italy?
59 studies are recruiting, active or about to start in Italy, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Italy. Retrieved 12 Nov 2026.
How much research is published on KRAS Inhibitors?
PubMed lists 440 papers on KRAS Inhibitors added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Italy

See all

Related on oncology

See the topic